Ascendis Pharma stock maintains leadership as UBS reiterates Buy rating

Investing.com - UBS has reiterated its Buy rating and $307.00 price target on Ascendis Pharma (NASDAQ:ASND) following competitor MBX’s clinical trial results for chronic hypoparathyroidism treatment. The price target aligns with the broader Wall Street consensus, as InvestingPro data shows analysts maintain a Strong Buy rating with targets ranging from $204 to $311.

MBX announced its weekly canvuparatide met the primary endpoint in its Phase 2 study, with 63% of treated patients maintaining normal calcium levels and independence from conventional therapy, compared to 31% for placebo patients.

Despite the positive competitor data, UBS believes Ascendis Pharma’s Yorvipath maintains clear leadership in the hypoparathyroidism treatment space, citing Yorvipath’s stronger placebo-adjusted response rates of 52.9% at 4 weeks and 69% at 26 weeks in its clinical trials.

UBS views the MBX data release as removing an overhang for Ascendis Pharma and sees upside potential for Yorvipath sales both near-term and long-term in what it estimates is a significant $10 billion-plus market.

The firm expects Ascendis Pharma to approach profitability with continued growth from Yorvipath and the anticipated launch of TransConCNP, which has a PDUFA date of November 30, 2025.

In other recent news, Ascendis Pharma has reported impressive financial results for Q2 2025, significantly beating earnings per share (EPS) forecasts. The company posted an actual EPS of -0.82, surpassing the predicted -1.27, which represents a 35.43% surprise. Additionally, Ascendis Pharma’s revenue exceeded expectations, reaching €158 million compared to the forecasted €142.38 million, marking an 11.01% surprise. The positive earnings news comes amid the global launch of Ascendis’ Yorvipath for hypoparathyroidism, which has shown strong initial results. Bank of America Securities has reiterated its Buy rating for Ascendis Pharma, maintaining a $230.00 price target, and has named it a top pick for 2025. The firm expects further growth as payor coverage for Yorvipath expands. These developments highlight Ascendis Pharma’s ongoing progress and favorable outlook according to analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.